2022.03.08Remiges Digestome Therapeutics announced first patient enrolled in Phase1 clinical trial of DGX-001
2022.01.10The Inflectis Bioscience received approval from French regulatory authority to conduct a Phase 2 Clinical Trial for IFB-088 for ALS
2021.06.23Remiges joined Series B Round of Glycomine in California
2021.05.27The core technology of Imel BioTherapeutics, Inc. was published in Scientific Reports
2021.04.09Remiges Ventures Closes Second Fund with $95 million; Launches RDiscovery Incubator
2020.12.10Remiges led the Series A round of finance for Cyrano Therapeutics in Washington D.C.